CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
GSK2256294 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03318783
NCT03318783Phase 2Completed
CompareCT.gov

Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial

Oregon Health and Science University·interventional·Posted Oct 24, 2017·Updated Jan 22, 2021

In Brief

A Phase 2 clinical trial evaluating GSK2256294 and Placebo for Subarachnoid Hemorrhage, Aneurysmal and 3 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Soluble epoxide hydrolase (sEH) is the metabolizing enzyme of epoxyeicosatrienoic acids (EETs), which may play a role in reducing neuroinflammation and regulating cerebral blood flow after subarachnoid hemorrhage (SAH). Hypotheses: Pharmacologic inhibition of the sEH enzyme is safe and will result in increased EETs availability in the blood and cerebrospinal fluid. This study is a double-blind, placebo-controlled, phase 1b randomized trial to evaluate the safety and efficacy of GSK2256294, a novel soluble epoxide hydrolase inhibitor in patients with aneurysmal SAH.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia, Vasospasm, Cerebral, Endothelial Dysfunction
CountriesUnited States
CollaboratorsFoundation for Anesthesia Education and Research, GlaxoSmithKline

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 24, 2017
Enrollment StartMay 2, 2018
Primary CompletionApr 3, 2019
Study CompletionJan 9, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.7 years ago

Interventions

GSK2256294drug

GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.

Placebodrug

Placebo will be administered in a single dose once daily enteral for a duration of 10 days.